Surgical and medical perspective on healthspan, GLP-1 therapy, body composition, and what actually determines whether metabolic health lasts.
How coffee's polyphenols actually reach your gut microbiome and get converted into short-chain fatty acids — a genuine mechanistic chain, with honest evidence-tier framing about how much of it is still animal-model research.
Why standard oral B12 supplementation often fails after gastric bypass specifically, and a broader look at other common causes — age, metformin, and acid-reducing medications — that deserve the same vigilance.
Prompted by a new study on semaglutide and asthma, a deeper look at four real mechanisms connecting metabolic dysfunction to lung inflammation — cytokine spillover, insulin-driven airway remodeling, lipotoxicity, and mitochondrial dysfunction.
Significant weight loss puts real strain on bone health — through genuinely different mechanisms depending on whether you've had surgery or are on a GLP-1, with real outcome data showing consistent supplementation makes a measurable difference.
Why ferritin, not just hemoglobin, is the marker that actually explains hair shedding during significant weight loss — including why standard lab “normal” ranges aren't the right target for hair health specifically.
A blueberry compound stabilized a key fat-burning protein in cultured mouse muscle cells. A genuinely interesting mechanism — and a clear example of why early cell-culture findings deserve real interest paired with real restraint.
Iron, vitamin D, calcium, B12, thiamine, protein, creatine, and collagen peptides aren't separate topics — they're the same foundational layer underneath every treatment goal on this site, from weight loss to athletic performance.
The one peptide the FDA committee actually rejected — and real placebo-controlled trials that found it didn't work. What honest skepticism looks like after five posts extending benefit of the doubt.
The same peptide, two completely different regulatory realities: a well-established topical cosmetic ingredient versus an unregulated injectable sold for entirely different claims. Closing out the individual peptide series.
Decades of research from a single lab, and what changed when independent researchers finally tested the core claim. A genuinely distinct evidence problem from anything else in this pillar.
The triple-agonist drug behind headlines of 30% weight loss, explained properly — including why its two separate Phase 3 trial programs (TRANSCEND and TRIUMPH) shouldn't be conflated, and why it isn't available yet.
A single molecule that transports fat and senses danger, found in muscle, fat, and reproductive tissue — giving real molecular mechanism to why metabolic dysfunction reaches into fertility and pregnancy complications.
At a Bryan Johnson longevity event, attendees kept asking for “the one thing” that extends life. Even Johnson himself doesn't believe in one thing — and neither does any serious evidence on this site.
Seven hospitalizations, a beautician selling vials for cash, and acute liver failure — a real, ongoing case that shows why verified sourcing and qualified medical oversight are both non-negotiable, not either/or.
A peptide with real foreign government approval and published human trials — but no Western verification. Why “unverified” and “unproven” are genuinely different claims, and this peptide is a clean example of the distinction.
The only peptide in this series with real prior FDA approval — what that approval actually covered, why it was withdrawn, and how thin the evidence actually is for its popular adult wellness uses.
A surgeon who also prescribes GLP-1s compares both honestly — efficacy, durability, cost, and risk — and makes the case that the real answer is often both together, not either/or.
A major new Nature Metabolism framework defines seven hallmarks of muscle health — and includes an important nuance on GLP-1 therapy, muscle mass, and weight cycling risk.
Metabolic syndrome's reach across every organ system — respiratory, reproductive, skin, kidney, infection risk, and a careful, honest look at cancer risk data, system by system.
A three-amino-acid anti-inflammatory peptide with a genuinely interesting mechanism and almost no direct human data — evaluated honestly, tier by tier, with a connection back to the site's core inflammation themes.
The most talked-about healing peptides, evaluated tier by tier — substantial animal data, thin uncontrolled human pilot studies, no completed RCTs, and a citation red flag worth knowing about.
The four-tier evidence framework used throughout this site for evaluating any peptide — separating regulatory status from evidence strength, so claims never sound more proven than they are.
What a peptide actually is, how it works mechanistically, and the real regulatory landscape — FDA-approved vs. compounded vs. research chemical — including a live July 2026 FDA committee vote.
The real STEP and SURMOUNT trial data — response variability, the trial-vs-real-world gap, and what the side effect and discontinuation numbers actually mean — read honestly, caveats included.
Two patients lost the exact same 40 pounds. Their DEXA scans told completely different stories. Why the scale can't distinguish fat loss from muscle loss, and why that gap matters more than the number itself.
What the STEP and SURMOUNT withdrawal trials actually show about weight regain after stopping GLP-1 therapy, why it happens, and why discontinuation deserves the same planning as starting treatment.
This practice doesn't manage diabetes as a primary condition, even though we prescribe medications also used to treat it. Here's why that boundary exists and how coordinated care actually works.
Why BCAA supplements alone can't finish what they start — leucine triggers muscle protein synthesis, but all nine essential amino acids are needed to actually build it.
How much protein, how often, and what to do when GLP-1 appetite suppression makes hitting your targets genuinely difficult — practical guidance for the weight-loss window.
An honest look at why bariatric surgery patients regain weight — the hormonal, anatomic, and muscle-loss mechanisms behind it, and why it's rarely just a story about willpower.
GLP-1 therapy, tesamorelin, and MOTS-c compared honestly across evidence tiers — what each actually does to leptin and adiponectin, and how strong the proof really is for each.
Leptin and adiponectin explained as adipose signaling molecules, not just biomarkers — why leptin resistance, not deficiency, is the real problem in obesity, and why the leptin:adiponectin ratio matters.
A new study found semaglutide slowed epigenetic aging markers in an HIV cohort — what the research actually shows, why researchers are urging caution, and how it connects to muscle and bone health.
Bringing it all together: how GLP-1 therapy, protein intake, and resistance training work as a coordinated stack — and why none of the three can substitute for the others.
Pharmacological “exercise mimetics” — MOTS-c, myostatin inhibitors, and AMPK-targeting compounds — explained honestly, including a direct safety warning about one substance sold illicitly online.
A layman summary of a major review on exercise metabolism — muscle fiber types, mitochondrial adaptation, endurance vs. resistance pathways, and myokines like IL-6 and apelin.
A new review argues sedentary people may benefit from eating less protein — while active people benefit from more. Why the real variable is exercise, not the protein number itself.
What actually reduces chronic inflammation — visceral fat reduction, exercise, sleep, and nutrition — plus a conservative look at where peptide therapy fits as an adjunct.
Why cardiorespiratory fitness predicts long-term health outcomes independent of weight — and a closing synthesis of the full nine-post Foundations series.
Why muscle is metabolically active tissue, what sarcopenia actually is, and how muscle loss connects to insulin resistance, inflammation, and visceral fat.
A deep dive on fatty liver disease — the MASLD/MASH naming update, how it's diagnosed and staged, and where treatment (including GLP-1 therapy) currently stands.
Why fat location matters more than fat amount — subcutaneous vs. visceral fat, why the scale and BMI can miss it, and how it directly connects to fatty liver disease.
The specific five-point diagnostic cluster behind metabolic syndrome, why it carries more urgency than any single risk factor, and how it drives endothelial dysfunction throughout the body.
Why chronic, low-grade inflammation is increasingly understood as a central driver behind metabolic disease, cardiovascular disease, and aging itself — and how it connects to nearly everything else on this site.
Obesity is one expression of metabolic disease, not the whole condition. Why the same underlying dysfunction shows up differently from patient to patient.
Why obesity is classified as a chronic disease, why BMI alone doesn't diagnose it, and what that reframing means for how it should actually be treated.
The baseline concept behind everything else on this site: what metabolic health actually means, and why weight was never supposed to be the target itself.
Weight loss was never the real goal. Why healthspan is the actual target, where GLP-1 therapy fits, and how peptide therapy plays a supporting role in comprehensive care.
What's actually behind the interest in very low-dose GLP-1 use, why the term “microdosing” undersells the seriousness of it, and where the evidence really stands.
More dose is not the same as more benefit. Why some patients do better finding their effective dose well within the standard range, rather than escalating to the top.
What's a normal adjustment period, what's a sign to call your provider, and the practical habits that make the early weeks of a GLP-1 more tolerable.
The most disciplined patients I've treated often struggled the most. Twenty-five years of surgery convinced me willpower was never the real variable.
In follow-up visits, the number on the scale is one of the last things I ask about. Here's what I track instead, and why I send patients for DEXA scans between visits.
Roughly a quarter to 40% of what's lost on a GLP-1, without structured support, is muscle — not fat. Here's why that gap matters more than the number on the scale.